165 related articles for article (PubMed ID: 20072892)
1. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
Asai T; Oku N
Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
[TBL] [Abstract][Full Text] [Related]
2. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.
Asai T; Miyazawa S; Maeda N; Hatanaka K; Katanasaka Y; Shimizu K; Shuto S; Oku N
Cancer Sci; 2008 May; 99(5):1029-33. PubMed ID: 18294280
[TBL] [Abstract][Full Text] [Related]
3. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
Asai T; Shimizu K; Kondo M; Kuromi K; Watanabe K; Ogino K; Taki T; Shuto S; Matsuda A; Oku N
FEBS Lett; 2002 Jun; 520(1-3):167-70. PubMed ID: 12044891
[TBL] [Abstract][Full Text] [Related]
4. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate.
Maeda N; Takeuchi Y; Takada M; Namba Y; Oku N
Bioorg Med Chem Lett; 2004 Feb; 14(4):1015-7. PubMed ID: 15013013
[TBL] [Abstract][Full Text] [Related]
6. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
Maeda N; Takeuchi Y; Takada M; Sadzuka Y; Namba Y; Oku N
J Control Release; 2004 Nov; 100(1):41-52. PubMed ID: 15491809
[TBL] [Abstract][Full Text] [Related]
7. Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model.
Yonezawa S; Asai T; Oku N
J Control Release; 2007 Apr; 118(3):303-9. PubMed ID: 17275944
[TBL] [Abstract][Full Text] [Related]
8. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
[TBL] [Abstract][Full Text] [Related]
9. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
[TBL] [Abstract][Full Text] [Related]
10. Liposomalized oligopeptides in cancer therapy.
Asai T; Oku N
Methods Enzymol; 2005; 391():163-76. PubMed ID: 15721380
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Guo P; Song S; Li Z; Tian Y; Zheng J; Yang X; Pan W
Int J Pharm; 2015; 486(1-2):356-66. PubMed ID: 25840274
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic photodynamic therapy with targeted liposomes.
Oku N; Ishii T
Methods Enzymol; 2009; 465():313-30. PubMed ID: 19913174
[TBL] [Abstract][Full Text] [Related]
13. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Kondo M; Asai T; Katanasaka Y; Sadzuka Y; Tsukada H; Ogino K; Taki T; Baba K; Oku N
Int J Cancer; 2004 Jan; 108(2):301-6. PubMed ID: 14639619
[TBL] [Abstract][Full Text] [Related]
14. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
Ichikawa K; Hikita T; Maeda N; Yonezawa S; Takeuchi Y; Asai T; Namba Y; Oku N
Biochim Biophys Acta; 2005 May; 1669(1):69-74. PubMed ID: 15843001
[TBL] [Abstract][Full Text] [Related]
17. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
18. Application of oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) lipid conjugates as steric barrier molecules in liposomal formulations.
Ansell SM; Kojic LD; Hankins JS; Sekirov L; Boey A; Lee DK; Bennett AR; Klimuk SK; Harasym TO; Dos Santos N; Semple SC
Bioconjug Chem; 1999; 10(4):653-66. PubMed ID: 10411464
[TBL] [Abstract][Full Text] [Related]
19. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy.
Murase Y; Asai T; Katanasaka Y; Sugiyama T; Shimizu K; Maeda N; Oku N
Cancer Lett; 2010 Jan; 287(2):165-71. PubMed ID: 19616372
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization.
Asai T; Kurohane K; Shuto S; Awano H; Matsuda A; Tsukada H; Namba Y; Okada S; Oku N
Biol Pharm Bull; 1998 Jul; 21(7):766-71. PubMed ID: 9703265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
